| Expression pattern: |
UP |
| Associated gene: |
MYO5A |
| Associated microRNA: |
miR-136-5p, miR-370-3p |
| Biological function: |
Circ-FNDC3B promotes ESCC cell viability, proliferation, invasion and tumor growth, and inhibits apoptosis; knockdown suppresses malignant progression and reduces tumor growth in vivo. |
| Molecular mechanism: |
Circ-FNDC3B acts as a ceRNA/miRNA sponge for miR-136-5p and miR-370-3p, thereby upregulating MYO5A expression and promoting ESCC progression. |
| Biological pathway or process: |
proliferation (promotes); invasion (promotes); metastasis (promotes); apoptosis (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High expression of circ-FNDC3B was related to TNM stage, tumor size and lymph node metastasis, and predicted poor prognosis in ESCC patients. |
| Description: |
Circ-FNDC3B is upregulated in ESCC tissues and cells and functions as an oncogenic circRNA. It promotes ESCC proliferation, invasion, metastasis-related phenotypes and xenograft tumor growth while suppressing apoptosis by sponging miR-136-5p and miR-370-3p to increase MYO5A expression. High circ-FNDC3B expression is associated with adverse clinicopathologic features and poorer overall survival. |
| Confidence score: |
0.7892 |